Enanta Pharmaceuticals
Manufacturing · Connecticut, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
4 Kingsbury Ave, Watertown, Connecticut,...Phone Number
(617) 607-0800Website
www.enanta.comRevenue
$69.2 MillionStock Symbol
ENTAIndustry
About Enanta Pharmaceuticals
Enanta Pharmaceuticals Org Chart
Is Enanta Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Enanta Pharmaceuticals launches new products
Click to see if Enanta Pharmaceuticals had a recent Job posting/layoffs
Earning: See what the market has to say on Enanta Pharmaceuticals recently announced quarterly report
Check out if Enanta Pharmaceuticals is spiking on competitors!
Enanta Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Enanta Pharmaceuticals has new funding data
Check if Enanta Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Enanta Pharmaceuticals
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Enanta Pharmaceuticals
Compare insights from companies similar to Enanta Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Enanta Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Enanta Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Enanta Pharmaceuticals.
Enanta Pharmaceuticals financials insights
Gather financial insights about Enanta Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
Series A
$5.1M
Series B
$20M
Series C
$17.6M
Series D
$12M
Series E
$20M
Grant
$42.7M
Stock Offering
$64.4M
Grant
$9.2M
Enanta Pharmaceuticals Tech Stack
A closer look at the technologies used by Enanta Pharmaceuticals
Most Recent Scoops
Enanta Pharmaceuticals News & Media
Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025 at 8:10 a.m. ET in New York, NY. A live webcast of the event will be accessible by visiting the “EvenEnanta Pharmaceuticals Announces Data from its Phase 2 Study of Zelicapavir in Children with Respiratory Syncytial Virus to be Presented at the 43rd Annual ESPID Meeting
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that data from the Company’s Phase 2 study of zelicapavir in young children infected with respiratory syncytial virus (RSV) will be available as an E-Poster at the 43rd Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID) 2025, being held May 2Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2025
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today reported financial results for its fiscal second quarter ended March 31, 2025. “Throughout the fiscal second quarter, Enanta remained squarely focused on executing across our virology and immunology pipeline. We are thrilled to have enrolled our target of 180 patients in RSVHR, a PhEnanta Pharmaceuticals Announces Respiratory Syncytial Virus Data Presentation at ESCMID Global 2025
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals Announces Respiratory Syncytial Virus Data Presentation at ESCMID Global 2025
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Enanta Pharmaceuticals
Founded in 1995, Enanta Pharmaceuticals is headquartered in Watertown, Massachusetts. They develop small molecule drugs for viral infections and liver diseases.... Read More
